Literature DB >> 9824103

Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP).

D G Tiniakos1, H Yu, H Liapis.   

Abstract

Expression of osteopontin (OPN) by ovarian tumors is not known. Neoplasms arising from the ovarian epithelium are distinguished in adenocarcinomas and borderline tumors (LMPs), which overall have a favorable prognosis even with omental implants. Tissues from primary ovarian tumors and their metastases from 30 patients (16 LMPs and 14 adenocarcinomas) were evaluated for OPN expression by immunohistochemistry, Western blotting, and in situ hybridization. OPN was weak or absent in 93% of ovarian adenocarcinomas or their metastases. In contrast, 81.5% of the LMPs and 50% of omental and lymph node implants were OPN positive (P < .028). Histological type, grade, or clinical stage did not correlate with OPN expression. Expression of OPN primarily by ovarian neoplasms with favorable prognosis is an intriguing new finding of potential importance in the pathogenesis of ovarian LMPs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824103     DOI: 10.1016/s0046-8177(98)90253-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer.

Authors:  Yasunori Hashiguchi; Hiroshi Tsuda; Christina A Bandera; Sadako Nishimura; Takeshi Inoue; Naoki Kawamura; Ross S Berkowitz; Samuel C Mok
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Authors:  Xianmin Luo; Megan K Ruhland; Ermira Pazolli; Anne C Lind; Sheila A Stewart
Journal:  Mol Cancer Res       Date:  2011-06-14       Impact factor: 5.852

3.  SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV.

Authors:  Kazuhiro Hamaoka; Sumiko Nagoshi; Kayoko Sugawara; Kayoko Naiki; Yoshihito Uchida; Mie Inao; Nobuaki Nakayama; Kenji Fujiwara; Satoshi Mochida
Journal:  Hepatol Int       Date:  2012-10-06       Impact factor: 6.047

Review 4.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

5.  Expression profiles of congenital renal dysplasia reveal new insights into renal development and disease.

Authors:  Sanjay Jain; Adrian A Suarez; John McGuire; Helen Liapis
Journal:  Pediatr Nephrol       Date:  2007-04-21       Impact factor: 3.714

6.  Clinical significance of osteopontin expression in cervical cancer.

Authors:  HanByoul Cho; Soon Won Hong; Youn Jin Oh; Min A Kim; Eun Suk Kang; Jong Min Lee; Sang Wun Kim; Sung Hoon Kim; Jae Hoon Kim; Young Tae Kim; Kook Lee
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-22       Impact factor: 4.553

7.  Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway.

Authors:  Guo-Xin Zhang; Zhi-Quan Zhao; Hong-Di Wang; Bo Hao
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

8.  Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development.

Authors:  Pi-Ling Chang; Yu-Hua Hsieh; Chao-Cheng Wang; M Margaret Juliana; Yuko Tsuruta; Laura Timares; Craig Elmets; Kang-Jey Ho
Journal:  J Dermatol Sci       Date:  2014-05-21       Impact factor: 4.563

9.  Osteopontin expression in normal skin and non-melanoma skin tumors.

Authors:  Pi-Ling Chang; Louie Harkins; Yu-Hua Hsieh; Patricia Hicks; Kraisorn Sappayatosok; Somchai Yodsanga; Somporn Swasdison; Ann F Chambers; Craig A Elmets; Kang-Jey Ho
Journal:  J Histochem Cytochem       Date:  2007-10-15       Impact factor: 2.479

10.  Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients.

Authors:  Danny T M Leung; Pak-Leong Lim; Tak-Hong Cheung; Raymond R Y Wong; So-Fan Yim; Margaret H L Ng; Frankie C H Tam; Tony K H Chung; Yick-Fu Wong
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.